Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides an overview of the Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline landscape. Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. Alzheimer's is a type of dementia. Symptoms include depression, social withdrawal, mood swings, irritability and aggressiveness and loss of inhibitions. Risk factors include age, family history and mild cognitive impairment. Treatment includes cholinesterase inhibitors and healthy life style. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Unknown stages are 6, 2 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Dementia Associated With Alzheimer's Disease. Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Dementia Associated With Alzheimer's Disease Overview 7 Therapeutics Development 8 Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview 8 Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis 9 Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies 10 Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 11 Dementia Associated With Alzheimer's Disease - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Dementia Associated With Alzheimer's Disease - Products under Development by Companies 15 Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes 16 Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development 17 Adamas Pharmaceuticals, Inc. 17 AgeneBio Inc. 18 Amarantus Bioscience Holdings, Inc. 19 Boehringer Ingelheim GmbH 20 Chase Pharmaceuticals Corporation 21 Eisai Co., Ltd. 22 H. Lundbeck A/S 23 MediPost Co., Ltd. 24 Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 (donepezil hydrochloride + solifenacin succinate) - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 BI-409306 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 E-2609 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 eltoprazine - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Gln-1062 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 levetiracetam - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 LUAF-20513 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Neurostem - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 salicylamine - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 TAK-070 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Dementia Associated With Alzheimer's Disease - Dormant Projects 59 Dementia Associated With Alzheimer's Disease - Discontinued Products 60 Dementia Associated With Alzheimer's Disease - Product Development Milestones 61 Featured News & Press Releases 61 Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation 61 Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer's Association International Conference 61 Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering & Investment Forum 63 Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website 63 Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression 64 Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference 66 Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer's Disease 67 Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia 67 Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer's Dementia 68 Jan 28, 2015: AgeneBio Receives Grant from Alzheimer's Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer's Dementia 69 May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories 70 May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda 70 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016 8 Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Comparative Analysis by Unknown Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 17 Dementia Associated With Alzheimer's Disease - Pipeline by AgeneBio Inc., H2 2016 18 Dementia Associated With Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 19 Dementia Associated With Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016 20 Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016 21 Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016 22 Dementia Associated With Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016 23 Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Assessment by Combination Products, H2 2016 26 Number of Products by Stage and Target, H2 2016 28 Number of Products by Stage and Mechanism of Action, H2 2016 30 Number of Products by Stage and Route of Administration, H2 2016 32 Number of Products by Stage and Molecule Type, H2 2016 34 Dementia Associated With Alzheimer's Disease - Dormant Projects, H2 2016 59 Dementia Associated With Alzheimer's Disease - Discontinued Products, H2 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.